Medical technology businesses in the South East Midlands can apply to cover 50% of their clinical evaluation costs, thanks to a project delivered by Medilink East Midlands and part-funded by the European Regional Development Fund (ERDF) and the East Midlands Academic Health Science Network (EMAHSN).Grants...
Business support is now available for life science companies in the South East Midlands, thanks to a project delivered by Medilink East Midlands and part-funded by the European Regional Development Fund (ERDF).ACTIS is a £2.1 million scheme, part-funded by ERDF, to provide support for eligible...
Platelet specialists Dr Natalia Dovlatova, Ann White and Bob Humphries announce the launch of their new company – ‘Platelet Services Limited’, which will be based in BioCity Nottingham, UK. Collectively, the team has decades of experience in the application of platelet function testing to drug...
Nottingham, UK – 29 May 2019 Sygnature Discovery, a leading drug discovery and pre-clinical services company, have appointed Dr Nick Moore as Senior Director, Business Development, in a newly-created role to promote the in vivo pharmacology and consultancy services offered by RenaSci, a wholly-owned subsidiary...
The achievements of four East Midlands life science companies have been recognised at the national Medilink UK awards. The Medilink UK awards recognise a variety of outstanding contributions to life sciences, in five different categories. These are Collaboration with the NHS, Export, Innovation, Outstanding Achievement and...
BioCity, the pioneering life science and business collective has announced co-investment into Rinri Therapeutics. A biotechnology company developing a novel cell-based therapy to restore hearing, Rinri Therapeutics have successfully secured £1.4 million in seed funding.BioCity’s recent investment in the biotech company, marks the 28th investment...
Nottingham-based leading DMPK provider, XenoGesis has reported a 78% increase in its exports from last year, with half of its revenue now coming from overseas.Founded in 2011, XenoGesis now has clients across six continents and has experienced consistent growth since day one, with export revenue...
Dr Rachel Hemsley, Global Head of Business Development at Nottingham-based leading DMPK provider XenoGesis, has been appointed to the Advisory Board of BioPartner, the trade organisation for internationalising life sciences companies.BioPartner works closely with UK bioscience sector stakeholders including regional networks, national trade associations, and...
Nottingham-based leading DMPK provider, XenoGesis, has been selected as a CRO partner to support the UK Medicines Discovery Catapult Virtual R&D Discovery Services platform worldwide.Based at BioCity Nottingham, XenoGesis is one of 22 world-class CROs chosen for the partnerships by the UK government’s Medicines Discovery...
BioAscent has been selected as one of the world-class CRO partners tasked with delivering support to the UK Medicines Discovery Catapult’s Virtual R&D Discovery Services platform.The Medicines Discovery Catapult has announced partnerships with a group of leading CROs, with the aim of boosting UK life...